Tag: birthControl

Articles

• Birth control pill use and breast cancer
• BRCA1 and BRCA2 mutation carriers

News

01/12/15

Early birth control pill use linked to premenopausal BC recurrence

Studies

• Breast Cancer in Users of Levonorgestrel-Releasing Intrauterine Systems Cite
  Mørch LS, Meaidi A, Corn G, Hargreave M, Wessel Skovlund C. Breast Cancer in Users of Levonorgestrel-Releasing Intrauterine Systems. JAMA. American Medical Association (AMA); 2024; 10.1001/jama.2024.18575
• Hormonal Contraception and Breast Cancer Risk for Carriers of Germline Mutations in BRCA1 and BRCA2 Cite
  Phillips K, Kotsopoulos J, Domchek SM, Terry MB, Chamberlain JA, Bassett JK, et al. Hormonal Contraception and Breast Cancer Risk for Carriers of Germline Mutations in BRCA1 and BRCA2. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2024; 10.1200/jco.24.00176
• Safety profile of levonorgestrel intrauterine system: Analysis of spontaneous reports submitted to FAERS Cite
  Chen L, Bao R, Tian X. Safety profile of levonorgestrel intrauterine system: Analysis of spontaneous reports submitted to FAERS. Heliyon. Elsevier BV; 2024; 10:e37112 10.1016/j.heliyon.2024.e37112
• Effects of Prenatal Chemical Exposures on Age at Menarche: A Scoping Review of Prospective Studies Cite
  Mahabir S, Sandquist M. Effects of Prenatal Chemical Exposures on Age at Menarche: A Scoping Review of Prospective Studies. Academia Oncology. Academia.edu Journals; 2024; 10.20935/acadonco7293
• Non-genetic factors and breast cancer: an umbrella review of meta-analyses Cite
  Yiallourou A, Pantavou K, Markozannes G, Pilavas A, Georgiou A, Hadjikou A, et al. Non-genetic factors and breast cancer: an umbrella review of meta-analyses. BMC Cancer. Springer Science and Business Media LLC; 2024; 24 10.1186/s12885-024-12641-8
• Systematic review and meta-analysis of lifestyle and reproductive factors associated with risk of breast cancer in Asian women Cite
  Ang BH, Teo SH, Ho W. Systematic review and meta-analysis of lifestyle and reproductive factors associated with risk of breast cancer in Asian women. Cancer Epidemiology, Biomarkers & Prevention. American Association for Cancer Research (AACR); 2024; 10.1158/1055-9965.epi-24-0005
• Exploring the Application of Digital Twin Technology in Investigating the Relationship Between Contraceptive Use and Breast Cancer Incidence Cite
  Bondhopadhyay B, Bansal H, Aggarwal N, Tanwar A. Exploring the Application of Digital Twin Technology in Investigating the Relationship Between Contraceptive Use and Breast Cancer Incidence. Advances in Medical Technologies and Clinical Practice. IGI Global; 2024;:358-384 10.4018/979-8-3693-5893-1.ch018
• Risk factors for breast cancer subtypes by race and ethnicity: A scoping review Cite
  Hurson AN, Ahearn TU, Koka H, Jenkins BD, Harris AR, Roberts S, et al. Risk factors for breast cancer subtypes by race and ethnicity: A scoping review. JNCI: Journal of the National Cancer Institute. Oxford University Press (OUP); 2024; 10.1093/jnci/djae172
• Association of Levonorgestrel-Releasing Intrauterine Device with Gynecologic and Breast Cancers: National Cohort Study in Sweden Cite
  Yi H, Zhang N, Huang J, Zheng Y, Hong Qh, Sundquist J, et al. Association of Levonorgestrel-Releasing Intrauterine Device with Gynecologic and Breast Cancers: National Cohort Study in Sweden. American Journal of Obstetrics and Gynecology. Elsevier BV; 2024; 10.1016/j.ajog.2024.05.011
• Abstract PS10-01: Hormonal Contraception and Breast Cancer Risk for Carriers of Germline Pathogenic Variants in BRCA1 and BRCA2 Cite
  Phillips K, Kotsopoulos J, Domchek S, Chamberlain J, Bassett J, Aeilts A, et al. Abstract PS10-01: Hormonal Contraception and Breast Cancer Risk for Carriers of Germline Pathogenic Variants in BRCA1 and BRCA2. Cancer Research. American Association for Cancer Research (AACR); 2024; 84:PS10-01-PS10-01 10.1158/1538-7445.sabcs23-ps10-01
• The unique risk factor profile of triple negative breast cancer: a comprehensive meta-analysis Cite
  Kumar N, Ehsan S, Banerjee S, Fernandez Perez C, Lhuilier I, Neuner J, et al. The unique risk factor profile of triple negative breast cancer: a comprehensive meta-analysis. JNCI: Journal of the National Cancer Institute. Oxford University Press (OUP); 2024; 10.1093/jnci/djae056
• Abstract B083: The associations of breast density, hormone use, family history, reproductive and lifestyle factors with triple negative breast cancer: a systematic review and meta-analysis Cite
  Kumar N, Ehsan S, Banerjee S, Perez CF, Lhuilier I, Neuner J, et al. Abstract B083: The associations of breast density, hormone use, family history, reproductive and lifestyle factors with triple negative breast cancer: a systematic review and meta-analysis. Cancer Research. American Association for Cancer Research (AACR); 2024; 84:B083-B083 10.1158/1538-7445.advbc23-b083
• Reproductive risk factors for breast cancer and association with novel breast density measurements among Hispanic, Black, and White women Cite
  Barnard ME, DuPré NC, Heine JJ, Fowler EE, Murthy DJ, Nelleke RL, et al. Reproductive risk factors for breast cancer and association with novel breast density measurements among Hispanic, Black, and White women. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2023; 10.1007/s10549-023-07174-w
• Is the Levonorgestrel Intruterine Device A Solution for All Problems? Cite
  Özer A. Is the Levonorgestrel Intruterine Device A Solution for All Problems?. Reproductive BioMedicine Online. Elsevier BV; 2023; 47:103450 10.1016/j.rbmo.2023.103450
• Navigating a plethora of progesterone receptors: Comments on the safety/risk of progesterone supplementation in women with a history of breast cancer or at high-risk for developing breast cancer Cite
  Diep CH, Mauro LJ, Lange CA. Navigating a plethora of progesterone receptors: Comments on the safety/risk of progesterone supplementation in women with a history of breast cancer or at high-risk for developing breast cancer. Steroids. Elsevier BV; 2023; 200:109329 10.1016/j.steroids.2023.109329
• Assessing the impact of contraceptive use on cancer risk among women of reproductive age – a systematic review Cite
  Jahanfar S, Mortazavi J, Lapidow A, Cu C, Abosy JA, Morris K, et al. Assessing the impact of contraceptive use on cancer risk among women of reproductive age – a systematic review. Research Square Platform LLC; 2023; 10.21203/rs.3.rs-3191980/v1
• A case-control study of 10,757 individuals to assess potentially modifiable risk factors, including stress, for breast cancer among Chinese patients in Hong Kong. Cite
  Yeo W, Yuen L, Tsoi KK, Chan EY, Kwok C, Soong SI, et al. A case-control study of 10,757 individuals to assess potentially modifiable risk factors, including stress, for breast cancer among Chinese patients in Hong Kong.. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2023; 41:e22522-e22522 10.1200/jco.2023.41.16_suppl.e22522
• Oral contraceptive use and breast cancer risk: A link beyond hormones Cite
  van Weers S. Oral contraceptive use and breast cancer risk: A link beyond hormones. Population Medicine. E.U. European Publishing; 2023; 5 10.18332/popmed/164498
• Combined and progestagen-only hormonal contraceptives and breast cancer risk: A UK nested case–control study and meta-analysis Cite
  Fitzpatrick D, Pirie K, Reeves G, Green J, Beral V. Combined and progestagen-only hormonal contraceptives and breast cancer risk: A UK nested case–control study and meta-analysis. PLOS Medicine. Public Library of Science (PLoS); 2023; 20:e1004188 10.1371/journal.pmed.1004188
• Effect of contraceptive hormonal therapy on mammographic breast density: A longitudinal cohort study Cite
  Hunt JT, Kamat R, Yao M, Sharma N, Batur P. Effect of contraceptive hormonal therapy on mammographic breast density: A longitudinal cohort study. Clinical Imaging. Elsevier BV; 2023; 97:62-67 10.1016/j.clinimag.2023.03.001
• Contraceptives and cancer risks in BRCA1/2 pathogenic variant carriers: a systematic review and meta-analysis Cite
  van Bommel MHD, IntHout J, Veldmate G, Kets CM, de Hullu JA, van Altena AM, et al. Contraceptives and cancer risks in BRCA1/2 pathogenic variant carriers: a systematic review and meta-analysis. Human Reproduction Update. Oxford University Press (OUP); 2022; 10.1093/humupd/dmac038
• Hormonal contraception and risk of breast cancer and breast cancer in situ among Swedish women 15–34 years of age: A nationwide register-based study Cite
  Niemeyer Hultstrand J, Gemzell-Danielsson K, Kallner HK, Lindman H, Wikman P, Sundström-Poromaa I. Hormonal contraception and risk of breast cancer and breast cancer in situ among Swedish women 15–34 years of age: A nationwide register-based study. The Lancet Regional Health - Europe. Elsevier BV; 2022; 21:100470 10.1016/j.lanepe.2022.100470
• Influence of the levonorgestrel-releasing intrauterine system on the risk of breast cancer: a systematic review Cite
  Zürcher A, Knabben L, Janka H, Stute P. Influence of the levonorgestrel-releasing intrauterine system on the risk of breast cancer: a systematic review. Archives of Gynecology and Obstetrics. Springer Science and Business Media LLC; 2022; 10.1007/s00404-022-06640-y
• Oral Contraceptive Use in BRCA1 and BRCA2 Mutation Carriers: Absolute Cancer Risks and Benefits. Cite
  Schrijver LH, Mooij TM, Pijpe A, Sonke GS, Mourits MJ, Andrieu N, et al. Oral Contraceptive Use in BRCA1 and BRCA2 Mutation Carriers: Absolute Cancer Risks and Benefits.. Apollo - University of Cambridge Repository; 2022; 10.17863/CAM.80147
• Oral contraceptives and risk of breast cancer and ovarian cancer in women with a BRCA1 or BRCA2 mutation: A meta-analysis of observational studies Cite
  Park J, Huang D, Chang YJ, Lim MC, Myung S. Oral contraceptives and risk of breast cancer and ovarian cancer in women with a BRCA1 or BRCA2 mutation: A meta-analysis of observational studies. Carcinogenesis. Oxford University Press (OUP); 2021; 10.1093/carcin/bgab107
• Oral contraceptive use by formulation and breast cancer risk by subtype in the Nurses' Health Study II: a prospective cohort study Cite
  Burchardt NA, Eliassen AH, Shafrir AL, Rosner B, Tamimi R, Kaaks R, et al. Oral contraceptive use by formulation and breast cancer risk by subtype in the Nurses' Health Study II: a prospective cohort study. American Journal of Obstetrics and Gynecology. Elsevier BV; 2021; 10.1016/j.ajog.2021.12.022
• Can harmful lifestyle, obesity and weight changes increase the risk of breast cancer in BRCA 1 and BRCA 2 mutation carriers? A Mini review Cite
  Daniele A, Divella R, Pilato B, Tommasi S, Pasanisi P, Patruno M, et al. Can harmful lifestyle, obesity and weight changes increase the risk of breast cancer in BRCA 1 and BRCA 2 mutation carriers? A Mini review. Hereditary Cancer in Clinical Practice. Springer Science and Business Media LLC; 2021; 19 10.1186/s13053-021-00199-6
• Racial/ethnic differences in postmenopausal breast cancer risk by hormone receptor status: the Multiethnic Cohort Study Cite
  Sarink D, White KK, Loo LW, Wu AH, Wilkens LR, Le Marchand L, et al. Racial/ethnic differences in postmenopausal breast cancer risk by hormone receptor status: the Multiethnic Cohort Study. International Journal of Cancer. Wiley; 2021; 10.1002/ijc.33795
• Levonorgestrel-Releasing Intrauterine System Use in Perimenopausal Women Cite
  Joo J, Shin J, Lee J, Kim M. Levonorgestrel-Releasing Intrauterine System Use in Perimenopausal Women. Journal of Menopausal Medicine. The Korean Society of Menopause; 2021; 27 10.6118/jmm.20038
• Combined Oral Contraceptives and Breast Cancer: an Unsolved Conundrum Cite
  Ammembal AMK, Udupa K. Combined Oral Contraceptives and Breast Cancer: an Unsolved Conundrum. Indian Journal of Gynecologic Oncology. Springer Science and Business Media LLC; 2021; 19 10.1007/s40944-021-00561-5
• Characterization of Benign Breast Diseases and Association With Age, Hormonal Factors, and Family History of Breast Cancer Among Women in Sweden Cite
  Johansson A, Christakou AE, Iftimi A, Eriksson M, Tapia J, Skoog L, et al. Characterization of Benign Breast Diseases and Association With Age, Hormonal Factors, and Family History of Breast Cancer Among Women in Sweden. JAMA Network Open. American Medical Association (AMA); 2021; 4:e2114716 10.1001/jamanetworkopen.2021.14716
• Contraceptive progestins with androgenic properties stimulate breast epithelial cell proliferation Cite
  Shamseddin M, De Martino F, Constantin C, Scabia V, Lancelot A, Laszlo C, et al. Contraceptive progestins with androgenic properties stimulate breast epithelial cell proliferation. EMBO Molecular Medicine. EMBO; 2021; 10.15252/emmm.202114314
• Meta-Analysis of Breast Cancer Risk in Levonorgestrel-Releasing Intrauterine System Users Cite
  Silva FR, Grande AJ, Lacerda Macedo AC, Colonetti T, Rocha MC, Rodrigues Uggioni ML, et al. Meta-Analysis of Breast Cancer Risk in Levonorgestrel-Releasing Intrauterine System Users. Clinical Breast Cancer. Elsevier BV; 2021; 10.1016/j.clbc.2021.03.013
• Levonorgestrel intrauterine system for endometrial protection in women with breast cancer on adjuvant tamoxifen Cite
  Romero SA, Young K, Hickey M, Su HI. Levonorgestrel intrauterine system for endometrial protection in women with breast cancer on adjuvant tamoxifen. Cochrane Database of Systematic Reviews. Wiley; 2020; 10.1002/14651858.cd007245.pub4
• Genetically predicted C-reactive protein associated with breast cancer risk: interrelation with estrogen and cancer molecular subtypes using a Mendelian randomization Cite
  Jung SY, Papp JC, Sobel EM, Pellegrini M, Yu H, Zhang Z. Genetically predicted C-reactive protein associated with breast cancer risk: interrelation with estrogen and cancer molecular subtypes using a Mendelian randomization. Research Square; 2020; 10.21203/rs.3.rs-57683/v1
• Reproductive Risk Factors of Inflammatory Breast Cancer according to Luminal, HER2-Overexpressing, and Triple-Negative Subtypes: A Case Comparison Study Cite
  Mejri N, El Benna H, Rachdi H, Labidi S, Benna M, Daoud N, et al. Reproductive Risk Factors of Inflammatory Breast Cancer according to Luminal, HER2-Overexpressing, and Triple-Negative Subtypes: A Case Comparison Study. Oncology Research and Treatment. S. Karger AG; 2020; 43:204-210 10.1159/000506691
• Use of oral contraceptives in BRCA mutation carriers and risk for ovarian and breast cancer: a systematic review Cite
  Huber D, Seitz S, Kast K, Emons G, Ortmann O. Use of oral contraceptives in BRCA mutation carriers and risk for ovarian and breast cancer: a systematic review. Archives of Gynecology and Obstetrics. Springer Science and Business Media LLC; 2020; 301:875-884 10.1007/s00404-020-05458-w
• Risk factors for estrogen receptor positive ductal carcinoma in situ of the breast in African American women Cite
  Bertrand KA, Bethea TN, Rosenberg L, Bandera EV, Khoury T, Troester MA, et al. Risk factors for estrogen receptor positive ductal carcinoma in situ of the breast in African American women. The Breast. Elsevier BV; 2020; 49:108-114 10.1016/j.breast.2019.10.009
• Breast cancer risk factors that are identical and differential associated with menopause status of women in Northeast Brazil Cite
  Gomes KAL, Jerônimo AFdA, Ramos RdO, Andrade LSdS, Weller M. Breast cancer risk factors that are identical and differential associated with menopause status of women in Northeast Brazil. Research Square; 2019; 10.21203/rs.2.14276/v1
• A prospective investigation of oral contraceptive use and breast cancer mortality: findings from the Swedish women’s lifestyle and health cohort Cite
  Nur U, El Reda D, Hashim D, Weiderpass E. A prospective investigation of oral contraceptive use and breast cancer mortality: findings from the Swedish women’s lifestyle and health cohort. BMC Cancer. Springer Science and Business Media LLC; 2019; 19 10.1186/s12885-019-5985-6
• Oral contraceptive and breast cancer: do benefits outweigh the risks? A case – control study from Jordan Cite
  Bardaweel SK, Akour AA, Al-Muhaissen S, AlSalamat HA, Ammar K. Oral contraceptive and breast cancer: do benefits outweigh the risks? A case – control study from Jordan. BMC Women's Health. Springer Science and Business Media LLC; 2019; 19 10.1186/s12905-019-0770-x
• Recent Use of Oral Contraceptives and Risk of Luminal B, Triple-Negative, and HER2-Overexpressing Breast Cancer Cite
  Lorona NC, Cook LS, Tang MC, Hill DA, Wiggins CL, Li CI. Recent Use of Oral Contraceptives and Risk of Luminal B, Triple-Negative, and HER2-Overexpressing Breast Cancer. Hormones and Cancer. Springer Science and Business Media LLC; 2019; 10:71-76 10.1007/s12672-019-00362-5
• The preventable burden of breast cancers for premenopausal and postmenopausal women in Australia: A pooled cohort study Cite
  Arriaga ME, Vajdic CM, Canfell K, MacInnis RJ, Banks E, Byles JE, et al. The preventable burden of breast cancers for premenopausal and postmenopausal women in Australia: A pooled cohort study. International Journal of Cancer. Wiley; 2019; 145:2383-2394 10.1002/ijc.32231
• The Impact of Hormonal Contraceptives on Breast Cancer Pathology Cite
  Dorchak JA, Maria S, Guarinoni JL, Duensing A, Somiari S, Cavanaugh J, et al. The Impact of Hormonal Contraceptives on Breast Cancer Pathology. Hormones and Cancer. Springer Science and Business Media LLC; 2018; 9:240-253 10.1007/s12672-018-0332-y
• Hair Coloring, Stress, and Smoking Increase the Risk of Breast Cancer: A Case-Control Study Cite
  Dianatinasab M, Fararouei M, Mohammadianpanah M, Zare-bandamiri M, Rezaianzadeh A. Hair Coloring, Stress, and Smoking Increase the Risk of Breast Cancer: A Case-Control Study. Clinical Breast Cancer. Elsevier BV; 2017; 17:650-659 10.1016/j.clbc.2017.04.012
• Reproductive risk factor associations with lobular and ductal carcinoma in the Carolina Breast Cancer Study Cite
  Williams LA, Nichols HB, Hoadley KA, Tse CK, Geradts J, Bell ME, et al. Reproductive risk factor associations with lobular and ductal carcinoma in the Carolina Breast Cancer Study. Cancer Causes & Control. Springer Science and Business Media LLC; 2017; 29:25-32 10.1007/s10552-017-0977-9
• Contemporary Hormonal Contraception and the Risk of Breast Cancer Cite
  Mørch LS, Skovlund CW, Hannaford PC, Iversen L, Fielding S, Lidegaard Ø. Contemporary Hormonal Contraception and the Risk of Breast Cancer. New England Journal of Medicine. Massachusetts Medical Society; 2017; 377:2228-2239 10.1056/nejmoa1700732
• Parity, hormones and breast cancer subtypes - results from a large nested case-control study in a national screening program Cite
  Ellingjord-Dale M, Vos L, Tretli S, Hofvind S, dos-Santos-Silva I, Ursin G. Parity, hormones and breast cancer subtypes - results from a large nested case-control study in a national screening program. Breast Cancer Research. Springer Science and Business Media LLC; 2017; 19 10.1186/s13058-016-0798-x
• The prognostic impact of COX-2 expression in breast cancer depends on oral contraceptive history, preoperative NSAID use, and tumor size Cite
  Simonsson M, Björner S, Markkula A, Nodin B, Jirström K, Rose C, et al. The prognostic impact of COX-2 expression in breast cancer depends on oral contraceptive history, preoperative NSAID use, and tumor size. International Journal of Cancer. Wiley; 2016; 140:163-175 10.1002/ijc.30432
• Abstract 1779: Risk factors for early-onset ER- and ER+ breast cancer in African American women Cite
  Bertrand KA, Rosenberg L, Palmer JR. Abstract 1779: Risk factors for early-onset ER- and ER+ breast cancer in African American women. Epidemiology. American Association for Cancer Research; 2016; 10.1158/1538-7445.am2016-1779
• Importance of hereditary and selected environmental risk factors in the etiology of inflammatory breast cancer: a case-comparison study Cite
  Moslehi R, Freedman E, Zeinomar N, Veneroso C, Levine PH. Importance of hereditary and selected environmental risk factors in the etiology of inflammatory breast cancer: a case-comparison study. BMC Cancer. Springer Science and Business Media LLC; 2016; 16 10.1186/s12885-016-2369-z
• Polycystic ovarian syndrome (PCOS), related symptoms/sequelae, and breast cancer risk in a population-based case–control study Cite
  Kim J, Mersereau JE, Khankari N, Bradshaw PT, McCullough LE, Cleveland R, et al. Polycystic ovarian syndrome (PCOS), related symptoms/sequelae, and breast cancer risk in a population-based case–control study. Cancer Causes & Control. Springer Science and Business Media LLC; 2016; 27:403-414 10.1007/s10552-016-0716-7
• Use of exogenous hormones and the risk of breast cancer: results from self-reported survey data with validity assessment Cite
  Heikkinen S, Koskenvuo M, Malila N, Sarkeala T, Pukkala E, Pitkäniemi J. Use of exogenous hormones and the risk of breast cancer: results from self-reported survey data with validity assessment. Cancer Causes & Control. Springer Science and Business Media LLC; 2015; 27:249-258 10.1007/s10552-015-0702-5
• Effect of lifestyle and reproductive factors on the onset of breast cancer in female BRCA 1 and 2 mutation carriers Cite
  Rieder V, Salama M, Glöckner L, Muhr D, Berger A, Tea M, et al. Effect of lifestyle and reproductive factors on the onset of breast cancer in female BRCA 1 and 2 mutation carriers. Molecular Genetics & Genomic Medicine. Wiley; 2015; 4:172-177 10.1002/mgg3.191
• Abstract 2747: Increasing age at first full-time pregnancy correlates to use of oral contraceptives before age 20 in women with a family history of breast cancer Cite
  Augustinsson A, Ellberg C, Kristoffersson U, Olsson H. Abstract 2747: Increasing age at first full-time pregnancy correlates to use of oral contraceptives before age 20 in women with a family history of breast cancer. Epidemiology. American Association for Cancer Research; 2015; 10.1158/1538-7445.am2015-2747
• Abstract 866: The proportion of breast and gynecological cancers in Australian women that can be attributed to the use of oral contraceptives and hormone replacement therapy Cite
  Jordan SJ, Wilson L, Whiteman D, Webb P. Abstract 866: The proportion of breast and gynecological cancers in Australian women that can be attributed to the use of oral contraceptives and hormone replacement therapy. Epidemiology. American Association for Cancer Research; 2015; 10.1158/1538-7445.am2015-866
• Abstract 855: History of oral contraceptive use in breast cancer patients and risk for early breast cancer events Cite
  Huzell L, Persson M, Simonsson M, Markkula A, Ingvar C, Rose C, et al. Abstract 855: History of oral contraceptive use in breast cancer patients and risk for early breast cancer events. Epidemiology. American Association for Cancer Research; 2015; 10.1158/1538-7445.am2015-855
• Abstract 860: Effects of breastfeeding and oral contraception use on the risk of breast cancer recurrence: A multinational study Cite
  Lehman TA, Shaik M, Modali RV, Hrinczenko B. Abstract 860: Effects of breastfeeding and oral contraception use on the risk of breast cancer recurrence: A multinational study. Epidemiology. American Association for Cancer Research; 2015; 10.1158/1538-7445.am2015-860
• Progestogens and membrane-initiated effects on the proliferation of human breast cancer cells Cite
  Ruan X, Neubauer H, Yang Y, Schneck H, Schultz S, Fehm T, et al. Progestogens and membrane-initiated effects on the proliferation of human breast cancer cells. Climacteric. Informa UK Limited; 2012; 15:467-472 10.3109/13697137.2011.648232
• Cancer Risk in Women Using the Levonorgestrel-Releasing Intrauterine System in Finland Cite
  Soini T, Hurskainen R, Grénman S, Mäenpää J, Paavonen J, Pukkala E. Cancer Risk in Women Using the Levonorgestrel-Releasing Intrauterine System in Finland. Obstetrics & Gynecology. Ovid Technologies (Wolters Kluwer Health); 2014; 124:292-299 10.1097/aog.0000000000000356
• Levonorgestrel-releasing intrauterine system and the risk of breast cancer: A nationwide cohort study Cite
  Soini T, Hurskainen R, Grénman S, Mäenpää J, Paavonen J, Joensuu H, et al. Levonorgestrel-releasing intrauterine system and the risk of breast cancer: A nationwide cohort study. Acta Oncologica. Informa UK Limited; 2015; 55:188-192 10.3109/0284186x.2015.1062538
• Association between abortion and breast cancer: an updated systematic review and meta-analysis based on prospective studies Cite
  Guo J, Huang Y, Yang L, Xie Z, Song S, Yin J, et al. Association between abortion and breast cancer: an updated systematic review and meta-analysis based on prospective studies. Cancer Causes & Control. Springer Science and Business Media LLC; 2015; 26:811-819 10.1007/s10552-015-0536-1
• A case–control analysis of oral contraceptive use and breast cancer subtypes in the African American Breast Cancer Epidemiology and Risk Consortium Cite
  Bethea TN, Rosenberg L, Hong C, Troester MA, Lunetta KL, Bandera EV, et al. A case–control analysis of oral contraceptive use and breast cancer subtypes in the African American Breast Cancer Epidemiology and Risk Consortium. Breast Cancer Research. Springer Science and Business Media LLC; 2015; 17 10.1186/s13058-015-0535-x
• History of oral contraceptive use in breast cancer patients: impact on prognosis and endocrine treatment response Cite
  Huzell L, Persson M, Simonsson M, Markkula A, Ingvar C, Rose C, et al. History of oral contraceptive use in breast cancer patients: impact on prognosis and endocrine treatment response. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2015; 149:505-515 10.1007/s10549-014-3252-8
• Oral contraceptive use and mortality after 36 years of follow-up in the Nurses' Health Study: prospective cohort study Cite
  Charlton BM, Rich-Edwards JW, Colditz GA, Missmer SA, Rosner BA, Hankinson SE, et al. Oral contraceptive use and mortality after 36 years of follow-up in the Nurses' Health Study: prospective cohort study. BMJ. BMJ; 2014; 349:g6356-g6356 10.1136/bmj.g6356
• Recent Oral Contraceptive Use by Formulation and Breast Cancer Risk among Women 20 to 49 Years of Age Cite
  Beaber EF, Buist DS, Barlow WE, Malone KE, Reed SD, Li CI. Recent Oral Contraceptive Use by Formulation and Breast Cancer Risk among Women 20 to 49 Years of Age. Cancer Research. American Association for Cancer Research (AACR); 2014; 74:4078-4089 10.1158/0008-5472.can-13-3400
• Age at first childbirth and oral contraceptive use are associated with risk of androgen receptor-negative breast cancer: the Malmö Diet and Cancer Cohort Cite
  Elebro K, Butt S, Dorkhan M, Jernström H, Borgquist S. Age at first childbirth and oral contraceptive use are associated with risk of androgen receptor-negative breast cancer: the Malmö Diet and Cancer Cohort. Cancer Causes & Control. Springer Science and Business Media LLC; 2014; 25:945-957 10.1007/s10552-014-0394-2
• Modifiers of Cancer Risk in BRCA1 and BRCA2 Mutation Carriers: A Systematic Review and Meta-Analysis Cite
  Friebel TM, Domchek SM, Rebbeck TR. Modifiers of Cancer Risk in BRCA1 and BRCA2 Mutation Carriers: A Systematic Review and Meta-Analysis. JNCI: Journal of the National Cancer Institute. Oxford University Press (OUP); 2014; 106 10.1093/jnci/dju091
• Oral Contraceptives and Breast Cancer Risk Overall and by Molecular Subtype Among Young Women Cite
  Beaber EF, Malone KE, Tang MC, Barlow WE, Porter PL, Daling JR, et al. Oral Contraceptives and Breast Cancer Risk Overall and by Molecular Subtype Among Young Women. Cancer Epidemiology Biomarkers & Prevention. American Association for Cancer Research (AACR); 2014; 23:755-764 10.1158/1055-9965.epi-13-0944
• Timing of oral contraceptive use and the risk of breast cancer in BRCA1 mutation carriers Cite
  Kotsopoulos J, Lubinski J, Moller P, Lynch HT, Singer CF, Eng C, et al. Timing of oral contraceptive use and the risk of breast cancer in BRCA1 mutation carriers. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2014; 143:579-586 10.1007/s10549-013-2823-4
• Oral Contraceptive Use and Risk of Breast, Cervical, Colorectal, and Endometrial Cancers: A Systematic Review Cite
  Gierisch JM, Coeytaux RR, Urrutia RP, Havrilesky LJ, Moorman PG, Lowery WJ, et al. Oral Contraceptive Use and Risk of Breast, Cervical, Colorectal, and Endometrial Cancers: A Systematic Review. Cancer Epidemiology Biomarkers & Prevention. American Association for Cancer Research (AACR); 2013; 22:1931-1943 10.1158/1055-9965.epi-13-0298
• Oral contraceptive use and risk of breast cancer: A meta-analysis of prospective cohort studies Cite
  Zhu H, Lei X, Feng J, Wang Y. Oral contraceptive use and risk of breast cancer: A meta-analysis of prospective cohort studies. The European Journal of Contraception & Reproductive Health Care. Informa UK Limited; 2012; 17:402-414 10.3109/13625187.2012.715357
• Injectable and Oral Contraceptive Use and Cancers of the Breast, Cervix, Ovary, and Endometrium in Black South African Women: Case–Control Study Cite
  Urban M, Banks E, Egger S, Canfell K, O'Connell D, Beral V, et al. Injectable and Oral Contraceptive Use and Cancers of the Breast, Cervix, Ovary, and Endometrium in Black South African Women: Case–Control Study. PLoS Medicine. Public Library of Science (PLoS); 2012; 9:e1001182 10.1371/journal.pmed.1001182
• Effect of Depo-Medroxyprogesterone Acetate on Breast Cancer Risk among Women 20 to 44 Years of Age Cite
  Li CI, Beaber EF, Chen Tang MT, Porter PL, Daling JR, Malone KE. Effect of Depo-Medroxyprogesterone Acetate on Breast Cancer Risk among Women 20 to 44 Years of Age. Cancer Research. American Association for Cancer Research (AACR); 2012; 72:2028-2035 10.1158/0008-5472.can-11-4064
• Oral contraceptives and risk of ovarian and breast cancers inBRCAmutation carriers: a meta-analysis Cite
  Cibula D, Zikan M, Dusek L, Majek O. Oral contraceptives and risk of ovarian and breast cancers inBRCAmutation carriers: a meta-analysis. Expert Review of Anticancer Therapy. Informa UK Limited; 2011; 11:1197-1207 10.1586/era.11.38
• Oral contraceptive formulation and risk of breast cancer Cite
  Marchbanks PA, Curtis KM, Mandel MG, Wilson HG, Jeng G, Folger SG, et al. Oral contraceptive formulation and risk of breast cancer. Contraception. Elsevier BV; 2012; 85:342-350 10.1016/j.contraception.2011.08.007
• Levonorgestrel-releasing and copper intrauterine devices and the risk of breast cancer Cite
  Dinger J, Bardenheuer K, Minh TD. Levonorgestrel-releasing and copper intrauterine devices and the risk of breast cancer. Contraception. Elsevier BV; 2011; 83:211-217 10.1016/j.contraception.2010.11.009
• Correlation of Age at Oral Contraceptive Pill Start with Age at Breast Cancer Diagnosis Cite
  Imkampe A, Bates T. Correlation of Age at Oral Contraceptive Pill Start with Age at Breast Cancer Diagnosis. The Breast Journal. Wiley; 2011; 18:35-40 10.1111/j.1524-4741.2011.01181.x
• Triple-negative breast cancer in Hispanic patients Cite
  Lara-Medina F, Pérez-Sánchez V, Saavedra-Pérez D, Blake-Cerda M, Arce C, Motola-Kuba D, et al. Triple-negative breast cancer in Hispanic patients. Cancer. Wiley; 2011; 117:3658-3669 10.1002/cncr.25961
• Association of Hormone-Related Characteristics and Breast Cancer Risk by Estrogen Receptor/Progesterone Receptor Status in the Shanghai Breast Cancer Study Cite
  Bao P, Shu XO, Gao Y, Zheng Y, Cai H, Deming SL, et al. Association of Hormone-Related Characteristics and Breast Cancer Risk by Estrogen Receptor/Progesterone Receptor Status in the Shanghai Breast Cancer Study. American Journal of Epidemiology. Oxford University Press (OUP); 2011; 174:661-671 10.1093/aje/kwr145
• Oral Contraceptive Use and Survival in Women with Invasive Breast Cancer Cite
  Lu Y, Ma H, Malone KE, Norman SA, Sullivan-Halley J, Strom BL, et al. Oral Contraceptive Use and Survival in Women with Invasive Breast Cancer. Cancer Epidemiology Biomarkers & Prevention. American Association for Cancer Research (AACR); 2011; 20:1391-1397 10.1158/1055-9965.epi-11-0022
• Reproductive History and Oral Contraceptive Use in Relation to Risk of Triple-Negative Breast Cancer Cite
  Phipps AI, Chlebowski RT, Prentice R, McTiernan A, Wactawski-Wende J, Kuller LH, et al. Reproductive History and Oral Contraceptive Use in Relation to Risk of Triple-Negative Breast Cancer. JNCI Journal of the National Cancer Institute. Oxford University Press (OUP); 2011; 103:470-477 10.1093/jnci/djr030
• Oral Contraceptive Use and Breast Cancer: A Prospective Study of Young Women Cite
  Hunter DJ, Colditz GA, Hankinson SE, Malspeis S, Spiegelman D, Chen W, et al. Oral Contraceptive Use and Breast Cancer: A Prospective Study of Young Women. Cancer Epidemiology Biomarkers & Prevention. American Association for Cancer Research (AACR); 2010; 19:2496-2502 10.1158/1055-9965.epi-10-0747
• A cluster of inflammatory breast cancer (IBC) in an office setting: Additional evidence of the importance of environmental factors in IBC etiology Cite
  Levine . A cluster of inflammatory breast cancer (IBC) in an office setting: Additional evidence of the importance of environmental factors in IBC etiology. Oncology Reports. Spandidos Publications; 2010; 24 10.3892/or_00000983
• Oral Contraceptive Use and Estrogen/Progesterone Receptor–Negative Breast Cancer among African American Women Cite
  Rosenberg L, Boggs DA, Wise LA, Adams-Campbell LL, Palmer JR. Oral Contraceptive Use and Estrogen/Progesterone Receptor–Negative Breast Cancer among African American Women. Cancer Epidemiology Biomarkers & Prevention. American Association for Cancer Research (AACR); 2010; 19:2073-2079 10.1158/1055-9965.epi-10-0428
• Meta-analysis of the risk factors of breast cancer concerning reproductive factors and oral contraceptive use Cite
  Dai Q, Liu B, Du Y. Meta-analysis of the risk factors of breast cancer concerning reproductive factors and oral contraceptive use. Frontiers of Medicine in China. Springer Science and Business Media LLC; 2009; 3:452-458 10.1007/s11684-009-0080-z
• Oral, injected and implanted contraceptives and breast cancer risk among U.S. Hispanic and non-Hispanic white women Cite
  Sweeney C, Giuliano AR, Baumgartner KB, Byers T, Herrick JS, Edwards SL, et al. Oral, injected and implanted contraceptives and breast cancer risk among U.S. Hispanic and non-Hispanic white women. International Journal of Cancer. Wiley; 2007; 121:2517-2523 10.1002/ijc.22970
• Risk Factors for Triple-Negative Breast Cancer in Women Under the Age of 45 Years Cite
  Dolle JM, Daling JR, White E, Brinton LA, Doody DR, Porter PL, et al. Risk Factors for Triple-Negative Breast Cancer in Women Under the Age of 45 Years. Cancer Epidemiology Biomarkers & Prevention. American Association for Cancer Research (AACR); 2009; 18:1157-1166 10.1158/1055-9965.epi-08-1005
• A Case-Control Study of Oral Contraceptive Use and Incident Breast Cancer Cite
  Rosenberg L, Zhang Y, Coogan PF, Strom BL, Palmer JR. A Case-Control Study of Oral Contraceptive Use and Incident Breast Cancer. American Journal of Epidemiology. Oxford University Press (OUP); 2008; 169:473-479 10.1093/aje/kwn360
• Age and Menopausal Effects of Hormonal Birth Control and Hormone Replacement Therapy in Relation to Breast Cancer Risk Cite
  Shantakumar S, Terry MB, Paykin A, Teitelbaum SL, Britton JA, Moorman PG, et al. Age and Menopausal Effects of Hormonal Birth Control and Hormone Replacement Therapy in Relation to Breast Cancer Risk. American Journal of Epidemiology. Oxford University Press (OUP); 2007; 165:1187-1198 10.1093/aje/kwm006
• Use of Four Biomarkers to Evaluate the Risk of Breast Cancer Subtypes in the Women's Contraceptive and Reproductive Experiences Study Cite
  Ma H, Wang Y, Sullivan-Halley J, Weiss L, Marchbanks PA, Spirtas R, et al. Use of Four Biomarkers to Evaluate the Risk of Breast Cancer Subtypes in the Women's Contraceptive and Reproductive Experiences Study. Cancer Research. American Association for Cancer Research (AACR); 2010; 70:575-587 10.1158/0008-5472.can-09-3460